These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://regantadt465058.amoblog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-60916791